Samsara BioCapital and Dr. Srinivas Akkaraju Report 6.4% Stake in Sutro Biopharma, Inc.

On May 15, 2026, a group of reporting persons led by Dr. Srinivas Akkaraju filed a Schedule 13G regarding their holdings in Sutro Biopharma, Inc. (STRO). The filing reveals that the reporting persons collectively beneficially own 1,062,872 shares of common stock, representing approximately 6.4% of the company based on 16,567,238 shares outstanding as of March 16, 2026. The ownership is distributed among several entities: Samsara BioCapital, L.P. holds 419,095 shares (2.5%), while Samsara Opportunity Fund, L.P. holds 643,777 shares (3.9%). Dr. Akkaraju, as the managing member of the general partners for both funds (Samsara BioCapital GP, LLC and Samsara Opportunity Fund GP, LLC), possesses shared voting and dispositive power over the total aggregate shares. This filing marks a new significant position for these entities, as their previous ownership was reported at 0%. The transaction triggering this requirement occurred on February 11, 2026. The reporting persons have certified that these shares were not acquired for the purpose of changing or influencing the control of the issuer.